{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:52:17Z","timestamp":1791582737730,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274269"],"award-info":[{"award-number":["82274269"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.imbio.2026.153215","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:11:49Z","timestamp":1783177909000},"page":"153215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["WD-3 improves anti-PD-L1 therapy by remodeling the tumor immune microenvironment through gut microbiota"],"prefix":"10.1016","volume":"231","author":[{"given":"Yifei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imbio.2026.153215_bb0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11523-016-0421-1","article-title":"Immunotherapy for Gastric Cancer: a Focus on Immune Checkpoints","volume":"11","author":"Alsina","year":"2016","journal-title":"Target. Oncol."},{"key":"10.1016\/j.imbio.2026.153215_bb0010","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature12726","article-title":"Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation","volume":"504","author":"Arpaia","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.imbio.2026.153215_bb0015","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Annals Oncol.: Offi. J. European Soc. Med. Oncol."},{"key":"10.1016\/j.imbio.2026.153215_bb0020","article-title":"817 Intratumoral CCR8+CD4+FoxP3+ regulatory T cell infiltration predicts inferior clinical outcomes but superior immunotherapeutic responsiveness in the patients with gastric cancer","volume":"13","author":"Cao","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.imbio.2026.153215_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae117","article-title":"A phase II study of cabozantinib and pembrolizumab in advanced gastric\/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors","volume":"29","author":"Dayyani","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.imbio.2026.153215_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.626172","article-title":"Post-Translational Regulations of Foxp3 in Treg Cells and their Therapeutic applications","volume":"12","author":"Dong","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2026.153215_bb0035","article-title":"Intratumoral Foxp3+ROR\u03b3t+ T cell infiltration determines poor prognosis and immunoevasive contexture in gastric cancer patients","volume":"71","author":"Fei","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.imbio.2026.153215_bb0040","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.imbio.2026.153215_bb0045","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.critrevonc.2019.09.003","article-title":"Gut microbiota and cancer: how gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy","volume":"143","author":"Gori","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.imbio.2026.153215_bb0050","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1038\/s41418-021-00753-8","article-title":"Multifaceted modes of action of the anticancer probiotic Enterococcus hirae","volume":"28","author":"Goubet","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.imbio.2026.153215_bb0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.imbio.2026.153215_bb0060","first-page":"581","article-title":"Weidiao-3 Mixture improves the clinical efficacy of immunotherapy for advanced gastric cancer by regulating intestinal Flora","volume":"45","author":"Huang","year":"2023","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"10.1016\/j.imbio.2026.153215_bb0065","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","article-title":"The Diversity of Gut Microbiome is Associated with favorable responses to Anti-Programmed Death 1 Immunotherapy in Chinese patients with NSCLC","volume":"14","author":"Jin","year":"2019","journal-title":"J. Thoracic Oncol.: Offi. Publ. Int. Associat. Study Lung Cancer"},{"key":"10.1016\/j.imbio.2026.153215_bb0070","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.7150\/jca.121363","article-title":"The immunosuppressive role of CCR8+ Tregs in gastric cancer","volume":"16","author":"Jinushi","year":"2025","journal-title":"J. Cancer"},{"key":"10.1016\/j.imbio.2026.153215_bb0075","first-page":"264","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.imbio.2026.153215_bb0080","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.trecan.2023.07.015","article-title":"Modulating Treg stability to improve cancer immunotherapy","volume":"9","author":"Kang","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.imbio.2026.153215_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"10.1016\/j.imbio.2026.153215_bb0090","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1186\/s12967-024-05867-4","article-title":"Association of PD-1+Treg\/PD-1+CD8 ratio and tertiary lymphoid structures with prognosis and response in advanced gastric cancer patients receiving preoperative treatment","volume":"22","author":"Liu","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.imbio.2026.153215_bb0095","doi-asserted-by":"crossref","first-page":"S1191","DOI":"10.1016\/j.annonc.2020.08.2296","article-title":"LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer (GC\/GEJC)\/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study","volume":"31","author":"Moehler","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.imbio.2026.153215_bb0100","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","article-title":"Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm","volume":"18","author":"Nakamura","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.imbio.2026.153215_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.imbio.2026.153215_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000422","article-title":"PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer","volume":"8","author":"Shen","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.imbio.2026.153215_bb0115","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.imbio.2026.153215_bb0120","doi-asserted-by":"crossref","first-page":"27509","DOI":"10.1073\/pnas.1921223117","article-title":"Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade","volume":"117","author":"Sun","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.imbio.2026.153215_bb0125","article-title":"Crosstalk between gut microbiota and cancer immunotherapy: present investigations and future perspective","volume":"8","author":"Tang","year":"2025","journal-title":"Research (Washington, D.C.)"},{"key":"10.1016\/j.imbio.2026.153215_bb0130","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/imm.13520","article-title":"Human FOXP3 and tumour microenvironment","volume":"168","author":"Wang","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.imbio.2026.153215_bb0135","doi-asserted-by":"crossref","first-page":"1404974","DOI":"10.3389\/fimmu.2024.1404974","article-title":"Advances in Foxp3+ regulatory T cells (Foxp3+ Treg) and key factors in digestive malignancies","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2026.153215_bb0140","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1158\/0008-5472.CAN-25-3071","article-title":"Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer","volume":"86","author":"Wang","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.imbio.2026.153215_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107148","article-title":"The interactions between traditional Chinese medicine and gut microbiota in cancers: current status and future perspectives","volume":"203","author":"Wei","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.imbio.2026.153215_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116866","article-title":"Echinacoside inhibits colorectal cancer metastasis via modulating the gut microbiota and suppressing the PI3K\/AKT signaling pathway","volume":"318","author":"Wei","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.imbio.2026.153215_bb0155","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.semcancer.2025.10.006","article-title":"Microbial modulation as a game changer: Boosting immunotherapy efficacy in breast cancer","volume":"117","author":"Xia","year":"2025","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.imbio.2026.153215_bb0160","first-page":"906","article-title":"Weitiao no. 3 (3) enhances the efficacy of anti-programmed cell death protein-1 immunotherapy by modulating the intestinal microbiota in an orthotopic model of gastric cancer mice","volume":"44","author":"Xiaona","year":"2024","journal-title":"J. Trad. Chinese Med. = Chung I Tsa Chih Ying Wen Pan"},{"key":"10.1016\/j.imbio.2026.153215_bb0165","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41423-025-01326-2","article-title":"The gut microbiota in cancer immunity and immunotherapy","volume":"22","author":"Xie","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.imbio.2026.153215_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2023.108202","article-title":"Engineering Escherichia coli Nissle 1917 as a microbial chassis for therapeutic and industrial applications","volume":"67","author":"Yu","year":"2023","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.imbio.2026.153215_bb0175","doi-asserted-by":"crossref","first-page":"2410474","DOI":"10.1080\/19490976.2024.2410474","article-title":"Synergistic activity of Enterococcus Faecium-induced ferroptosis via expansion of IFN-\u03b3(+)CD8(+) T cell population in advanced hepatocellular carcinoma treated with sorafenib","volume":"16","author":"Yu","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.imbio.2026.153215_bb0180","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11655-009-0107-y","article-title":"Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine","volume":"15","author":"Zhou","year":"2009","journal-title":"Chin. J. Integr. Med."},{"key":"10.1016\/j.imbio.2026.153215_bb0185","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.trecan.2021.01.010","article-title":"Gut Microbiota in Cancer Immune Response and Immunotherapy","volume":"7","author":"Zhou","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.imbio.2026.153215_bb0190","first-page":"226","article-title":"WD-3 inhibits the proliferation of breast cancer cells by regulating the glycolytic pathway","volume":"20","author":"Zhu","year":"2020","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"10.1016\/j.imbio.2026.153215_bb0195","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.immuni.2024.07.020","article-title":"Long-distance microbial mechanisms impacting cancer immunosurveillance","volume":"57","author":"Zitvogel","year":"2024","journal-title":"Immunity"}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298526000616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298526000616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:06:28Z","timestamp":1791579988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171298526000616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0171298526000616"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2026.153215","relation":{},"ISSN":["0171-2985"],"issn-type":[{"value":"0171-2985","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WD-3 improves anti-PD-L1 therapy by remodeling the tumor immune microenvironment through gut microbiota","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2026.153215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"153215"}}